Daxor Corporation is the global leader in blood volume measurement technology, providing the only FDA-cleared diagnostic—the Blood Volume Analyzer (BVA)—capable of quantifying total blood volume, plasma volume, and red cell volume with greater than 95% accuracy compared to patient-specific ideals. In the high-stakes ICU environment, Daxor replaces "hemodynamic guesswork" with objective data, addressing the fluid management challenges inherent in sepsis, ARDS, and surgical blood loss. Peer-reviewed studies demonstrate that BVA-guided care can lead to a 66% reduction in mortality and a 44% change in treatment strategy by identifying volume derangements that indirect markers like CVP often miss. Beyond clinical outcomes, Daxor’s technology improves hospital efficiency by reducing ICU length of stay by an average of 2.6 days. At SCCM 2026, Daxor is showcasing its newly FDA-cleared next-generation analyzer; developed in partnership with the U.S. Department of Defense, this portable, easy-to-use system brings rapid, lab-quality volume measurement into the clinical workflow to optimize patient care.
